The Effect of MDT Plus SDM on Survival Benefit of Advanced Gastric Cancer

NCT ID: NCT06432205

Last Updated: 2024-05-29

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 121 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-11-09
• Study Completion Date: 2025-08-31

Brief Summary

The goal of this observational study is to learn about the long-term effect of surgery in metastatic gastric cancer patients who are accessed as having opportunity for surgery under Multi-disciplinary Team (MDT) evaluation. The main question it aims to answer is:

Does surgery extend survival time in metastatic gastric cancer patients who are accessed as having opportunity for surgery under Multi-disciplinary Team (MDT) evaluation?

Detailed Description

Select metastatic gastric cancer patients that have the opportunity to undergo any forms of surgery through MDT. Then further evaluate these patients' risks and benefits. Let patients make their finally decision through shared-decision making (SDM). According to the actual decision, the patients are divided into surgery group and non-surgery group.

Conditions

Gastric Cancer

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

surgery group

metastatic gastric cancer patients who are assessed as having the opportunity for surgery finally choose to undergo surgery after MDT plus SDM.

surgery

Intervention Type: PROCEDURE

any forms of surgery, such as all tumor resection, partial tumor resection and palliative tumor resection surgery

non-surgery group

metastatic gastric cancer patients who are assessed as having the opportunity for surgery finally choose not to undergo surgery after MDT plus SDM.

No interventions assigned to this group

Interventions

surgery

any forms of surgery, such as all tumor resection, partial tumor resection and palliative tumor resection surgery

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Age ≥18 years old;
• Participate in the formal MDT discussion and evaluate feasible surgical treatment;
• Gastric adenocarcinoma or gastroesophageal junction adenocarcinoma confirmed by histology;
• Immunotherapy must be received during the treatment;
• At least 1 distant metastatic organs, and the number of metastases is ≥1;
• The subject line blood routine (within 7 days) and biochemical indicators (within 14 days) meet the following standards:

hemoglobin≥90g/L； absolute count of neutral granulocytes (ANC) ≥1.5×10^9/L； platelets≥100×10^9/L； Alt, AST≤ 2.5 times the normal upper limit，≤5 times the normal upper limit value (with liver metastasis)； ALP ≤ 2.5 times the normal upper limit，≤5 times the normal upper limit (with liver or bone metastasis)； total bilirubin<1.5 times the normal upper limit value of serum； serum creatinine<1.5 times normal upper limit； albumin≥30g/L；

• ECOG 0 ～ 1 point;
• The expected life span is ≥3 months;
• Cardiopulmonary function is basically normal;
• Women and spouses of childbearing age are willing to adopt effective contraceptive methods.

Exclusion Criteria

• Those who do not meet the above selected standards or have chemotherapy contraindications;
• Combined with other primary malignant tumors;
• Pregnancy, lactating women or women of childbearing age and spouses refuse to adopt effective contraceptive methods;
• History of organ transplantation (including bone marrow autologous transplantation and peripheral stem cell transplantation);
• History of long -term treatment of steroids (Note: Short -term users discontinue drugs> 2 weeks can be selected);
• History of peripheral nervous system disorders or obvious mental disorders and central nervous system disorders;
• Accompanied by severe infection;
• Accompanied by swallowing difficulties, complete or incomplete digestive tract obstruction, gastrointestinal bleeding, perforation, etc.;
• Severe liver disease (such as liver cirrhosis, etc.), kidney disease, respiratory disease, or chronic system diseases such as diabetes, hypertension, high blood pressure;
• Coronary heart disease with obvious clinical symptoms, such as: congestive heart failure, obvious symptoms, cardiac disorders, hypertension, or myocardial infarction seizures, or inadequate heart function within 6 months;
• Persons without legal capacity, medical or ethical reasons affecting the continuation of research.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Peking University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Xiaotian Zhang, professor

Role: CONTACT

zhangxiaotianmed@163.com

010-88196561

Facility Contacts

Xiaotian Zhang, Professor

Role: primary

Other Identifiers

2023YJZ66

Identifier Type: -

Identifier Source: org_study_id